Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles

Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery

(2017) Dunja Sobot et al.   Nature Communications

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

(2016) Alison M. Betts et al.   AAPS Journal

PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma

(2016) Alice Gaudin et al.   BIOMATERIALS

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

Docetaxel prodrug liposomes for tumor therapy: characterization,in vitroandin vivoevaluation

(2016) Guolian Ren et al.   DRUG DELIVERY

Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition

(2016) Yao Jiang et al.   JOURNAL OF CONTROLLED RELEASE

Accumulating nanoparticles by EPR: A route of no return

(2016) Romeo Ngoune et al.   JOURNAL OF CONTROLLED RELEASE

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

Cocktails for cancer with a measure of immunotherapy

(2016) Heidi Ledford   NATURE

Enhanced anti-tumor efficacy of paclitaxel with PEGylated lipidic nanocapsules in presence of curcumin and poloxamer: In vitro and in vivo studies

(2016) Mohammed Anwar et al.   PHARMACOLOGICAL RESEARCH

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection

(2015) S. Sadekar et al.   AAPS Journal

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

(2015) X. Paoletti et al.   ANNALS OF ONCOLOGY

Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer

(2015) Manon Launay et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

(2015) T. C. Chang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer

(2015) Patricia LoRusso et al.   CANCER RESEARCH

Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer

(2015) Zhen Liang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle

(2015) Marc P. Kai et al.   JOURNAL OF CONTROLLED RELEASE

Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody

(2015) Justyna M. Meissner et al.   JOURNAL OF CONTROLLED RELEASE

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

(2015) Rebecca S. Heist et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine

(2015) Sébastien Benzekry et al.   SEMINARS IN CANCER BIOLOGY

Nanodrug Delivery Systems: A Promising Technology for Detection, Diagnosis, and Treatment of Cancer

(2014) Anish Babu et al.   AAPS PHARMSCITECH

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates

(2014) Dan Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetics and pharmacodynamics ofnab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel

(2014) Nianhang Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Biodistribution, Tumor Uptake and Efficacy of 5-FU-Loaded Liposomes: Why Size Matters

(2014) Raphaelle Fanciullino et al.   PHARMACEUTICAL RESEARCH

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

(2014) Neil Desai et al.   Translational Oncology

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology

(2014) Sihem Ait-Oudhia et al.   Pharmaceutics

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

(2013) A H Ko et al.   BRITISH JOURNAL OF CANCER

Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs

(2013) Raphaelle Fanciullino et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Biodistribution and Pharmacokinetics of EGFR-Targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-Bearing Mice

(2013) Jing Xu et al.   MOLECULAR PHARMACEUTICS

In Vitro and In Vivo Evaluation of Lipofufol, a New Triple Stealth Liposomal Formulation of Modulated 5-Fu: Impact on Efficacy and Toxicity

(2013) Raphaelle Fanciullino et al.   PHARMACEUTICAL RESEARCH

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

(2013) Kirsten Achilles Poon et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Challenges in Development of Targeted Liposomal Therapeutics

(2012) Rupa R. Sawant et al.   AAPS Journal

Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

(2012) Jeffrey A. Silverman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

(2012) Susan O'Brien et al.   JOURNAL OF CLINICAL ONCOLOGY

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

(2012) H. K. Erickson et al.   MOLECULAR CANCER THERAPEUTICS

Meta-analysis of Nanoparticulate Paclitaxel Delivery System Pharmacokinetics and Model Prediction of Associated Neutropenia

(2012) Sihem Ait-Oudhia et al.   PHARMACEUTICAL RESEARCH

Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases

(2011) D. Cosco et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Nanoparticle PEGylation for imaging and therapy

(2011) Jesse V Jokerst et al.   Nanomedicine

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

(2009) Glenn E Palomaki et al.   GENETICS IN MEDICINE

Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage

(2009) Hilary Shmeeda et al.   JOURNAL OF CONTROLLED RELEASE

Protein nanoparticles as drug carriers in clinical medicine

(2008) Michael J. Hawkins et al.   ADVANCED DRUG DELIVERY REVIEWS

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

(2008) Neil P. Desai et al.   ANTI-CANCER DRUGS

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel

(2008) E. R. Gardner et al.   CLINICAL CANCER RESEARCH

Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer

(2008) Kimberley M. Laginha et al.   JOURNAL OF DRUG TARGETING

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

(2008) Paul Tardi et al.   LEUKEMIA RESEARCH